Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

56%
Genetic Cohort Participants
Enrollment Goal: 600

60%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment: 423

100%
Control Participants
Enrollment: 196

100%
Subjects with SWEDD
Enrollment: 64

100%
Prodromal Participants
Enrollment: 65

Last Update: December 12, 2016

 

More about study cohorts >

Landmark Study to Find Biomarkers


Biomarkers are the critical missing links in the search for better Parkinson’s disease treatments.

The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate people with Parkinson’s disease and those at greater risk of developing the disease, as well as healthy controls. The goal is to identify one or more biomarkers of Parkinson’s disease progression.   This longitudinal study, following over 1,000 participants for up to 8 years, is taking place at 33 clinical sites in the United States, Europe, Israel and Australia.

Critical data and biospecimens are currently available for the research community.

The comprehensive PPMI database and biorepository, includes:

>  Clinical and behavioral assessments
>  Imaging data
>  Biospecimens: cerebral spinal fluid, DNA, RNA, plasma, serum, urine and cell lines

Use the database effectively.

The PPMI Statistics Core at the University of Iowa provides invaluable information about the PPMI database during this 13 minute webinar.

PPMI is made possible by the concerted efforts of a number of collaborators and sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

LATEST NEWS FROM PPMI

Consortium to Develop Model of Parkinson’s Progression Using PPMI Data

Parkinson’s UK and the Critical Path Institute (C-Path) in Tucson, Arizona, recently launched the Critical Path for Parkinson’s consortium (CPP) to create a quantitative model of Parkinson’s progression from its earliest stages that will allow researchers to optimize clinical trial design for faster and more effective testing of new therapies. To achieve this goal, C-Path […]


PPMI Sub-study Provides Engineered Stem Cells for Parkinson’s Research

The Parkinson’s Progression Markers Initiative (PPMI) announced the availability of induced pluripotent stem cells (iPSCs) for research to speed new therapies and deeper understanding of Parkinson’s disease. iPSCs are “man-made” stem cells created by taking a person’s own skin or blood cells and reprogramming them. These stem cells can then be made into other types […]


PPMI Industry & Scientific Advisory Board Chair on why PPMI is important

Vera Kiyasova, PhD, Clinical Development Leader at Servier, is the current chair of the PPMI Industry & Scientific Advisory Board (ISAB). She spoke to us about the importance of both PPMI and industry’s involvement with the study.


Database tutorial webinar from the PPMI Statistics Core

Chelsea Caspell-Garcia and Eric Foster from the PPMI Statistics Core at the University of Iowa provide invaluable information about the PPMI database during this 13 minute webinar.


PPMI Participants Share Perspectives on Landmark Biomarker Study

In late spring, investigators from the Parkinson’s Progression Markers Initiative (PPMI) gathered in New York City for their annual meeting. Also in attendance were a handful of PPMI participants who are members of the PPMI Patient Committee. These research volunteers penned a letter to the PPMI community sharing their gratitude to the many people involved […]


Learn More